Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 37%
Hold 26%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences is a strong company with potential for future growth, specifically in their transcatheter and surgical heart valve products. They have a diverse portfolio and are expanding into new markets, which could lead to further revenue and margin growth. However, there are some potential risks that could impact their growth, such as market challenges and regulatory delays, but overall, Edwards Lifesciences has a positive outlook for the future.

Bears say

Edwards Lifesciences is a leader in the medical devices and equipment industry, but its premium valuation already reflects its strong market position and growth potential. While the company's TAVR business has stabilized, reaching its potential can still be impacted by updates and guidelines. Other new product launches may support growth, but challenges such as tariffs and expenses may hinder margin expansion. The stock may be attractive for its long-term growth potential, but we rate it as a HOLD due to limited upside beyond what the company has already committed to.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.